Analysts on Wall Street project that Moderna (MRNA) will announce quarterly loss of $2.65 per share in its forthcoming report, representing a decline of 581.8% year over year. Revenues are projected ...

Looking ahead, BofA cut its 2025 and 2026 revenue forecasts by 18% and 15%, respectively. While negative EPS projections ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $34 from $41 and keeps an Underperform rating on the shares ...

Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 21.0% in the fourth quarter, ...

O n Friday, February 7, a hearing took place in the Montana state legislature on a bill that would ban the use of mRNA vaccines in humans. The bill was sponsored by State Representative Greg Kmetz ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

The claim that Moderna’s CEO confessed to creating a COVID vaccine before the pandemic is false. His remarks at Davos 2023 ...